Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01313936 · ClinicalTrials.gov registry record · Phase 1
High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01313936 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 32 participants.
The verdict
NCT01313936, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a pilot study to determine whether doses of 15 mCi/kg and 18 mCi/kg of 131I-MIBG are tolerable when given with irinotecan/vincristine on a one week schedule to children and young adults with high-risk refractory/relapsed neuroblastoma.
Interventions
- DRUG Metaiodobenzylguanidine (MIBG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-03 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01313936
The ClinicalTrials.gov registry entry for NCT01313936 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metaiodobenzylguanidine (MIBG) is the first listed.
NCT01313936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01313936 about?
NCT01313936 is a clinical study titled "High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma". This is a pilot study to determine whether doses of 15 mCi/kg and 18 mCi/kg of 131I-MIBG are tolerable when given with irinotecan/vincristine on a one week schedule to children and young adults with high-risk refractory/relapsed neuroblastoma.
What is the current status of trial NCT01313936?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2011-03. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01313936?
The interventions under investigation include: Metaiodobenzylguanidine (MIBG) (DRUG).
Who is sponsoring clinical trial NCT01313936?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.